No Image

Bulls, Bears: Sepsis and Anti-Infectives in the Public Markets

September 28, 2012 OneMedPlace Team 0

The threat of infection in hospital and other treatment facilities have dramatically increased over the last few years. Antibiotics and other therapies have become impotent against certain pathogens and infections, increasing the need for research funding for creating new antibiotics. These three companies have the potential to solve a significant unmet medical need.

No Image

Good News for Market-Leading Stent

March 31, 2009 bjohnson56 0

A new study by Abbott Laboratories found that their drug-coated stent, Xience V, is more effective in the long term than a competitor’s. According to the Wall Street Journal, the data showed that rates of major cardiovascular events plateaued at 6.4% in the second and third years after Xience was implanted.